EP300 and acute myeloid leukemia: Taken together, these results suggest that p300/CBP inhibitors preserve efficacy in FLT3 inhibitor-resistant AML models harboring TKD mutations and demonstrate a synergistic effect when combined with a FLT3 inhibitor.